| CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li, PA Villalobos, ... Cancer discovery 8 (9), 1156-1175, 2018 | 382 | 2018 |
| STING pathway expression identifies NSCLC with an immune-responsive phenotype CM Della Corte, T Sen, CM Gay, K Ramkumar, L Diao, RJ Cardnell, ... Journal of Thoracic Oncology 15 (5), 777-791, 2020 | 112 | 2020 |
| TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins ST Kundu, CL Grzeskowiak, JJ Fradette, LA Gibson, LB Rodriguez, ... Nature communications 9 (1), 2731, 2018 | 108 | 2018 |
| Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy R Soundararajan, JJ Fradette, JM Konen, S Moulder, X Zhang, ... Cancers 11 (5), 714, 2019 | 92 | 2019 |
| ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer R Manshouri, E Coyaud, ST Kundu, DH Peng, SA Stratton, K Alton, ... Nature communications 10 (1), 1-15, 2019 | 80 | 2019 |
| The good, the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors JM Konen, JJ Fradette, DL Gibbons Cells 9 (1), 52, 2019 | 72 | 2019 |
| Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers DH Peng, BL Rodriguez, L Diao, PO Gaudreau, A Padhye, JM Konen, ... Nature communications 12 (1), 2606, 2021 | 52 | 2021 |
| ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism DH Peng, ST Kundu, JJ Fradette, L Diao, P Tong, LA Byers, J Wang, ... Science translational medicine 11 (483), eaaq1238, 2019 | 50 | 2019 |
| Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer M Yamauchi, DL Gibbons, C Zong, JJ Fradette, N Bota-Rabassedas, ... Matrix biology 91, 8-18, 2020 | 44 | 2020 |
| In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer CL Grzeskowiak, ST Kundu, X Mo, AA Ivanov, O Zagorodna, H Lu, ... Nature communications 9 (1), 2732, 2018 | 39 | 2018 |
| Tumor immunology and immunotherapy of non-small-cell lung cancer T Cascone, J Fradette, M Pradhan, DL Gibbons Cold Spring Harbor perspectives in medicine, a037895, 2021 | 36 | 2021 |
| IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion R Bajaj, ST Kundu, CL Grzeskowiak, JJ Fradette, KL Scott, CJ Creighton, ... Oncogene 39 (37), 5979-5994, 2020 | 32 | 2020 |
| Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression L Chen, X Yi, S Goswami, YH Ahn, JD Roybal, Y Yang, L Diao, D Peng, ... Oncoimmunology 5 (11), e1234570, 2016 | 26 | 2016 |
| Dance of the Golgi: understanding Golgi dynamics in cancer metastasis R Bajaj, AN Warner, JF Fradette, DL Gibbons Cells 11 (9), 1484, 2022 | 25 | 2022 |
| Ntrk1 promotes resistance to PD-1 checkpoint blockade in mesenchymal Kras/p53 mutant lung cancer JM Konen, BL Rodriguez, JJ Fradette, L Gibson, D Davis, R Minelli, ... Cancers 11 (4), 462, 2019 | 25 | 2019 |
| A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer A Padhye, C Ungewiss, JJ Fradette, BL Rodriguez, JL Albritton, JS Miller, ... Scientific reports 9 (1), 4819, 2019 | 25 | 2019 |
| Targeting of CD40 and PD-L1 pathways inhibits progression of oral premalignant lesions in a carcinogen-induced model of oral squamous cell carcinoma JA Monteiro de Oliveira Novaes, T Hirz, I Guijarro, M Nilsson, MA Pisegna, ... Cancer Prevention Research 14 (3), 313-324, 2021 | 22 | 2021 |
| Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC JM Konen, BL Rodriguez, A Padhye, JK Ochieng, L Gibson, L Diao, ... Cancer research 81 (5), 1398-1412, 2021 | 19 | 2021 |
| MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs JK Ochieng, ST Kundu, R Bajaj, B Leticia Rodriguez, JJ Fradette, ... Oncogene 39 (43), 6719-6732, 2020 | 18 | 2020 |
| Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer A Padhye, JM Konen, BL Rodriguez, JJ Fradette, JK Ochieng, L Diao, ... JCI insight 6 (17), 2021 | 15 | 2021 |
